English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

R. Edward Coleman1*, Stanley J. Goldsmith2, Richard B. Noto3, Kimberly R. Pearson4, Katherine A. Kacena4, John A. Barrett4, Norman D. LaFrance4, John W. Babich4 * Corresponding author 1 Duke University Medical School, Durham, NC 27710 2 New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY 10065 3 Rhode Island Medical Imaging, Rhode Island Hospital, Providence, RI 02903 4 Molecular Insight Pharmaceuticals, Inc., Cambridge, MA 02142

One Year Follow-Up for the Phase I MTD Study of Ultratrace Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma (Pheo)